•Base Therapeutics is a pioneering biotechnology company focused on developing innovative cell and gene therapy solutions. Founded in Shanghai, China, the company is at the forefront of genetic medicine, aiming to create groundbreaking treatments for various diseases, including cancer and autoimmune disorders.
•
•Base Therapeutics’ core technology revolves around its proprietary base editing platform, which allows for precise genetic modifications without causing double-strand DNA breaks. Base Therapeutics is developing two main product pipelines: BASE-NK and BEAT-CART. The BASE-NK pipeline focuses on creating enhanced natural killer (NK) cell therapies, while the BEAT-CART pipeline aims to develop improved chimeric antigen receptor T-cell (CAR-T) therapies.
